Sanjay Srivastava
Sanjay Srivastava, Ph.D., is a Managing Director in Accenture’s Life Sciences Strategy & Consulting practice, leading Cell & Gene Therapy CoE and practice. Sanjay has broad and deep expertise in the underpinning science and business challenges in developing and launching both in-vivo and ex-vivo C>s. He has global expertise in R&D, supply chain, manufacturing, and commercial operations. He is active in the industry, driving harmonization and simplicity in C> practices and has presented his insights at various CGT conferences.
ARTICLES BY SANJAY SRIVASTAVA
-
![iStock-470938482]( "Shaping A System That Enables Patients To Access High-Cost Cell & Gene Therapies")
Shaping A System That Enables Patients To Access High-Cost Cell & Gene Therapies7/28/2021The health and life sciences industry needs to create an effective financial system to support the complex new payment structures being adopted for cell and gene therapies.
-
![Human cell]( "Scaling Cell and Gene Therapy Manufacturing Operations")
Scaling Cell and Gene Therapy Manufacturing Operations10/13/2020Manufacturing autologous cell therapy products faces few key complications, which is typically why CAR-T manufacturing runs at two or three sigma operations.
-
![Sanjay Srivastava]( "Part 2: Cell And Gene Therapy Is Transforming Healthcare")
Part 2: Cell And Gene Therapy Is Transforming Healthcare2/13/2020Healthcare sector players are neither adequately equipped nor strategically placed near patients to accommodate the anticipated volume of clinical trials to evaluate cell and gene therapies (CGT) in development. While the industry is adjusting and deploying the required capabilities, the transformation is evolving and incomplete. Real change requires rethinking how current sector players are adopting and how they will operate in the future.
-
![Blue cells 450x300]( "How Cell And Gene Therapy Is Transforming Healthcare")
How Cell And Gene Therapy Is Transforming Healthcare2/4/2020But overcoming challenges is key to meeting CGT promise.
